XML 36 R26.htm IDEA: XBRL DOCUMENT v3.22.1
Segments
 3 Months Ended
Mar. 31, 2022
Segment Reporting [Abstract]  
Segments Segments
The Company's CODM assesses the operating performance of and allocates resources for several operating segments using Segment Adjusted EBITDA as a basis. Management believes this financial metric is a key indicator of operating results since it excludes noncash revenues and expenses that are not reflective of the underlying business performance of an individual enterprise. The Company defines Segment Adjusted EBITDA as net income (loss) before (i) interest expense, (ii) income tax expense or benefit, (iii) depreciation and amortization, (iv) stock-based compensation expense, (v) loss on settlement agreements where noncash consideration is paid, (vi) adjustments for accrued bonuses paid in equity awards, (vii) gain or loss on disposals of assets, (viii) loss on impairment of goodwill and other noncurrent assets, (ix) equity in net loss of affiliates, and (x) recognition of previously deferred revenue associated with upfront and milestone payments as well as cash outflows from capital expenditures and investments in affiliates, but includes proceeds from the sale of assets in the period sold.
Because the Company uses Segment Adjusted EBITDA as its primary measure of segment performance, it has included this measure in its discussion of segment operating results. The Company has also disclosed revenues from external customers and intersegment revenues for each reportable segment. Corporate expenses are not allocated to the segments and are managed at a consolidated level. The CODM does not use total assets by segment to evaluate segment performance or allocate resources, and accordingly, these amounts are not required to be disclosed. The Company's segment presentation excludes amounts related to the operations of MBP Titan which are reported as discontinued operations (Note 3).
For the three months ended March 31, 2022, the Company's reportable segments were (i) Biopharmaceuticals, (ii) Exemplar, and (iii) Trans Ova. These identified reportable segments met the quantitative thresholds to be reported separately for the three months ended March 31, 2022. See Note 2 for a description of Biopharmaceuticals. See Note 1 for a description of Exemplar and Trans Ova.
Segment Adjusted EBITDA by reportable segment was as follows:
Three Months Ended 
 March 31,
20222021
Biopharmaceuticals
$(11,620)$(8,854)
Exemplar3,558 1,806 
Trans Ova5,397 6,421 
Segment Adjusted EBITDA for reportable segments$(2,665)$(627)
The table below reconciles Segment Adjusted EBITDA for reportable segments to consolidated net loss from continuing operations before income taxes:
Three Months Ended 
 March 31,
20222021
Segment Adjusted EBITDA for reportable segments$(2,665)$(627)
Remove cash paid for capital expenditures, net of proceeds from sale of assets, and cash paid for investments in affiliates1,314 597 
Add recognition of previously deferred revenue associated with upfront and milestone payments1,446 307 
Other expenses:
Interest expense(2,069)(4,539)
Depreciation and amortization(3,292)(3,523)
Loss on disposals of assets(125)(121)
Impairment losses(482)— 
Stock-based compensation expense(3,562)(5,415)
Adjustment related to accrued bonuses paid in equity awards1,698 — 
Equity in net loss of affiliates(1)(3)
Other— (7)
Unallocated corporate costs(10,060)(8,194)
Eliminations(1,511)(371)
Consolidated net loss from continuing operations before income taxes$(19,309)$(21,896)
Revenues by reportable segment were as follows:
Three Months Ended March 31, 2022
Biopharmaceuticals
ExemplarTrans OvaTotal
Revenues from external customers$84 $5,429 $26,508 $32,021 
Intersegment revenues1,446 — 147 1,593 
Total segment revenues$1,530 $5,429 $26,655 $33,614 
Three Months Ended March 31, 2021
Biopharmaceuticals
ExemplarTrans OvaTotal
Revenues from external customers$178 $3,257 $21,076 $24,511 
Intersegment revenues241 — 107 348 
Total segment revenues$419 $3,257 $21,183 $24,859 
The table below reconciles total segment revenues from reportable segments to total consolidated revenues:
Three Months Ended 
 March 31,
20222021
Total segment revenues from reportable segments$33,614 $24,859 
Elimination of intersegment revenues(1,593)(348)
Total consolidated revenues$32,021 $24,511 

For the three months ended March 31, 2022 and 2021,13.0% and 8.4%, respectively, of total consolidated revenue was attributable to one customer in the Exemplar segment.
As of March 31, 2022 and December 31, 2021, the Company had $4,148 and $4,463, respectively, of long-lived assets in foreign countries. The Company recognized revenues derived in foreign countries totaling $205 and $99 for the three months ended March 31, 2022 and 2021, respectively